# US 5,708,140 A · Production of proteins using 7B2 protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,708,140 A
- Document ID: US5708140A
- Status: Granted
- Kind: A
- Application number: 08/244,492
- Filed: 1994-09-02
- Granted: 1998-01-13
- Earliest claimed: 1991-11-29
- Assignees: Ciba-Geigy Corporation
- Inventors: Gerardus Julianus Maria Martens; Bhabatosh Chaudhuri; Christine Stephan
- Web page: https://patentgrep.com/patent/US5708140A

## CPC

- C07K 1/1133: {by redox-reactions involving cystein/cystin side chains}
- C07K 14/4722: {G-proteins}
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C07K 14/665: derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C12N 15/67: General methods for enhancing the expression
- C12N 15/81: for yeasts
- C07K 2319/02: containing a signal sequence
- C12N 2799/023: where the vector is derived from a poxvirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention lies in the field of genetic engineering and, in particular, is concerned with the use of 7B2 as chaperone in vivo or in vitro. The invention accordingly concerns a method for producing a desired protein in vivo with the aid of recombinant cells capable of expressing 7B2 and of expressing and secreting said desired protein. Another aspect is accordingly an in vitro method for the deaggregation or prevention of aggregation of protein by treating the protein with 7B2.

## Claims

### Claim 1

A method for the deaggregation or prevention of aggregation of a monomeric protein in vitro, characterized in that the protein or aggregates thereof are treated with 7B2 in sufficient quantity and for sufficient time to result in a solution of essentially monomeric protein that is a bioactive protein.

### Claim 2 (depends on 1)

A method according to claim 1, characterized in that the bioactive protein is selected from the group consisting of peptide hormones, neuropeptides, growth factors and coagulation factors.

### Claim 3 (depends on 2)

A method according to claim 2, characterized in that the bioactive protein is selected from the group consisting of a peptide hormone or neuropeptide.

### Claim 4 (depends on 3)

A method according to claim 3, characterized in that the bioactive protein is IGF-1.

### Claim 5 (depends on 1)

A method according to claim 1, characterized in that the 7B2 is human 7B2.

### Claim 6 (depends on 5)

A method according to claim 5, characterized in that the bioactive protein is selected from the group consisting of peptide hormones, neuropeptides, growth factors and coagulation factors.

### Claim 7 (depends on 6)

A method according to claim 6, characterized in that the bioactive protein is selected from the group consisting of peptide hormone or neuropeptide.

### Claim 8 (depends on 7)

A method according to claim 7, characterized in that the bioactive protein is IGF-1.